Global Angioedema Treatment Industry Insights: Market Size, Growth Analysis and Forecast

Report ID : 1290368 | Published : February 2025 | Study Period : 2023-2033 | Format : PDF + Excel

The market size of the Angioedema Treatment Industry is categorized based on Drug Type (Corticosteroids, Antihistamines, Epinephrine, Biologics, Other Treatment Options) and Route of Administration (Oral, Intravenous, Subcutaneous, Intramuscular) and Indication Type (Hereditary Angioedema, Acquired Angioedema, Idiopathic Angioedema) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The Angioedema Treatment Industry was worth $1.2 billion in 2023 and is forecasted to reach $2.5 billion by 2033, growing at a CAGR of 8.1% over the period 2024-2033. This report covers various segments and analyzes the key trends and factors influencing the market significantly.

With the increasing incidence of angioedema, which is marked by angioedema swelling of skin and mucous membranes, the health care sector has begun treating Angioedema Treatment Market as one of the lucrative markets. Healthcare professionals are well aware of the notion that this particular swelling can arise due to allergies, medications or even hereditary factors which in return adds to the need for treatments for this angioedema. There is a gradually increasing realization among the patients which is additionally fueling the demand for effective treatment options.

The last few years have seen the introduction of newer treatment options like antihistamines, corticosteroids, monoclonal antibody therapy and so on. These new therapies look to not only treat the symptoms of angioedema but also address the condition root cause for a more sustainable solution for the patients. The forecast growth in the Angioedema Treatment Market corresponds with the expectations of the healthcare industry in relation to the need for effective measures to be employed so that patients can have a better quality of life while simultaneously easing the load on healthcare systems.

Additionally, the growing investment of pharmaceutical companies in research and development, along with the incorporation of new technologies in treatment delivery, marks the possibility of expansion to the market. The Angioedema Treatment Market is anticipated to develop in the future and feature new avenues for expansion and creativity as stakeholders look to cover the broad spectrum of patient needs.

 

ATTRIBUTES	DETAILS
STUDY PERIOD	2023-2033
BASE YEAR	2023
FORECAST PERIOD	2024-2033
HISTORICAL PERIOD	2023-2024
UNIT	VALUE (USD BILLION)
KEY COMPANIES PROFILED	Takeda Pharmaceutical Company Limited, Pfizer Inc., CSL Behring, Shire (Acquired by Takeda), Berkshire Hathaway, Sanofi, Amgen Inc., LFB Biomedicaments, BioCryst Pharmaceuticals Inc., Horizon Therapeutics plc, Novartis AG
SEGMENTS COVERED	By Drug Type - Corticosteroids, Antihistamines, Epinephrine, Biologics, Other Treatment Options By Route of Administration - Oral, Intravenous, Subcutaneous, Intramuscular By Indication Type - Hereditary Angioedema, Acquired Angioedema, Idiopathic Angioedema By Geography - North America, Europe, APAC, Middle East Asia & Rest of World.

---

Angioedema Treatment Industry Dynamics

The Angioedema Treatment Industry is undergoing significant changes due to various dynamic factors. This section delves into the key drivers, restraints, opportunities, and challenges that are shaping the market landscape.

Market Drivers

1. Technological Advancements
2. Increasing Consumer Demand
3. Regulatory Support
4. Globalization

Market Restraints

1. High Operational Costs
2. Regulatory Challenges
3. Market Saturation

Market Opportunities

1. Emerging Markets
2. Product Innovation
3. Strategic Partnerships

Market Challenges

1. Technological Disruptions
2. Supply Chain Issues
3. Changing Consumer Preferences

---

Key Players in the Angioedema Treatment Industry

This report provides an in-depth analysis of both established and rising industry participants. It provides broad lists of important companies organized by the types of products they offer and other market-related factors. In addition to characterizing these companies, the report contains the year each player entered the market, which is useful for research analysis by the study's analysts.

• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• CSL Behring
• Shire (Acquired by Takeda)
• Berkshire Hathaway
• Sanofi
• Amgen Inc.
• LFB Biomedicaments
• BioCryst Pharmaceuticals Inc.
• Horizon Therapeutics plc
• Novartis AG

---

Customization Options

Verified Industry Insights offers one of the following report customization options to our respectable clients :

Company Profiling

● Detailed profiling of additional market players (up to three players)
● SWOT analysis of key players (up to three players)

Competitive Benchmarking

● Benchmarking of key players on the following parameters : Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research

Verified Industry Insights offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected] or call us at +1 743 222 5439

© 2024 Verified Industry Insights. All Rights Reserved